Q-omics provides the consensus-scored RN7SKP65 profile across patient tissues and cancer cell-line models. RN7SKP65 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, RN7SKP65 is differentially expressed in 1, with the highest sampling consensus in LUAD. Additionally, RN7SKP65 RNA expression shows 5,548 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CESC, LUAD, and STAD as cancer lineages where RN7SKP65 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SKP65 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SKP65 survival associations across molecular data types. RN7SKP65 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SKP65 RNA expression–survival associations across cancer types. High RN7SKP65 expression shows unfavorable associations in CESC, TGCT, THYM, ACC, READ and OV. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for RN7SKP65 RNA expression.
This table summarizes RN7SKP65 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SKP65. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SKP65 shows higher tumor expression in LUAD. The LUAD box plot shows higher RN7SKP65 RNA expression in tumor versus normal tissue (log2 FC = +0.045, t-test p = .012).
This table shows molecular features associated with RN7SKP65 in patient tissues and cancer cell lines. In patient samples, RN7SKP65 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
